Skip to main content

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

BALA CYNWYD, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Fiesta Restaurant Group, Inc. (Nasdaq - FRGI)

Under the terms of the agreement, Fiesta will be acquired by Authentic Restaurant Brands (“ARB”). Each share of Fiesta common stock will be entitled to receive $8.50 per share in cash. The investigation concerns whether the Fiesta Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether ARB is paying fair value to shareholders of the Company. For example, the deal consideration is below the 52-week high of $9.28 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/fiesta-restaurant-group-inc-nasdaq-frgi/.

Veritiv Corporation (NYSE - VRTV)

Under the terms of the agreement, Veritiv will be acquired by an affiliate of Clayton, Dubilier & Rice, LLC (“CD&R”). Each share of Veritiv common stock will be entitled to receive $170 per share in cash. The investigation concerns whether the Veritiv Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether CD&R is paying fair value to shareholders of the Company.

Additional information can be found at https://www.brodskysmith.com/cases/veritiv-corporation-nyse-vrtv/.

New Relic, Inc. (NYSE - NEWR)

Under the terms of the Merger Agreement, New Relic will be acquired by Francisco Partners. New Relic shareholders will receive $87.00 in cash for each share they hold. The equity value of the deal is approximately $6.5 billion. The investigation concerns whether the New Relic Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Francisco Partners is paying fair value to shareholders of the Company.

Additional information can be found at https://www.brodskysmith.com/cases/new-relic-inc-nyse-newr/.

Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

Under the terms of the Merger Agreement, Reata will be acquired by Biogen Inc. (Nasdaq - BIIB). Reata shareholders will receive $172.50 in cash for each share they hold. The enterprise value of the deal is approximately $7.3 billion. The investigation concerns whether the Reata Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Biogen is paying fair value to shareholders of the Company.

Additional information can be found at https://www.brodskysmith.com/cases/reata-pharmaceuticals-inc-nasdaq-reta/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.